COSCIA, MARCO
 Distribuzione geografica
Continente #
EU - Europa 199
NA - Nord America 121
AS - Asia 41
Totale 361
Nazione #
US - Stati Uniti d'America 118
IE - Irlanda 97
SE - Svezia 46
DE - Germania 25
HK - Hong Kong 24
SG - Singapore 15
IT - Italia 12
CZ - Repubblica Ceca 9
UA - Ucraina 6
CA - Canada 3
FR - Francia 2
GB - Regno Unito 1
IM - Isola di Man 1
IN - India 1
IR - Iran 1
Totale 361
Città #
Dublin 97
Hong Kong 24
Chandler 15
Bremen 12
Lawrence 12
Princeton 12
Boardman 11
Jacksonville 10
Brno 9
Singapore 9
Munich 5
Somaglia 4
Piemonte 3
Santa Clara 3
Gunzenhausen 2
Ottawa 2
San Mateo 2
Arona 1
Cagliari 1
Douglas 1
Frankfurt am Main 1
Grafing 1
Naples 1
Palermo 1
Toronto 1
Vergiate 1
Wilmington 1
Zanjan 1
Totale 243
Nome #
Bidirectional linkage between the B-cell receptor and NOTCH1 in chronic lymphocytic leukemia and in Richter’s syndrome: therapeutic implications 39
Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study 39
Prognostic significance of PET/CT in patients with chronic lymphocytic leukemia (CLL) treated with frontline chemoimmunotherapy 39
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 34
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 32
Efficacy of idelalisib and rituximab in relapsed/refractory chronic lymphocytic leukemia treated outside of clinical trials. A report of the Gimema Working Group 30
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 29
Prediction of outcomes in chronic lymphocytic leukemia patients treated with ibrutinib: Validation of current prognostic models and development of a simplified three-factor model 27
Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs 27
Prognostic impact and risk factors of infections in patients with chronic lymphocytic leukemia treated with ibrutinib 27
Efficacy of Front-Line Ibrutinib and Rituximab Combination and the Impact of Treatment Discontinuation in Unfit Patients with Chronic Lymphocytic Leukemia: Results of the Gimema LLC1114 Study 26
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 25
Totale 374
Categoria #
all - tutte 3.601
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.601


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20207 0 0 0 0 0 0 2 0 1 3 1 0
2020/202116 1 0 1 0 3 2 3 0 3 0 3 0
2021/202241 0 0 2 1 1 0 1 1 1 1 11 22
2022/2023203 12 10 20 0 13 13 1 20 101 1 5 7
2023/202468 5 6 6 1 8 0 18 0 0 0 3 21
2024/202539 10 0 12 1 7 9 0 0 0 0 0 0
Totale 374